{"name":"Stevanato Group","slug":"stevanato","ticker":"STVN","exchange":"NYSE","domain":"stevanatogroup.com","description":"Stevanato Group is an Italian multinational company headquartered in Piombino Dese, Padua – Italy. \nFounded in 1949, it is also active in the glass tube forming technology and inspection systems sector.","hq":"Piombino Dese, Italy","founded":1935,"employees":"6010","ceo":"Franco Stevanato","sector":"Pharma Packaging & Drug Delivery Devices","stockPrice":18,"stockChange":0.14,"stockChangePercent":0.78,"marketCap":"$5.7B","metrics":{"revenue":1405677608.6011777,"revenueGrowth":6.6,"grossMargin":29.2,"rdSpend":0,"netIncome":165129682.3750944,"cash":131163551.50680001,"dividendYield":0.35,"peRatio":30,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lupron patent cliff ($1.4B at risk)","drug":"Lupron","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Eprex patent cliff ($1.1B at risk)","drug":"Eprex","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Stevanato Group Reports Q4 2023 Earnings","summary":"Stevanato Group reported its Q4 2023 earnings, with revenue increasing by 12% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Stevanato Group Partners with Biotech Company for Customized Packaging Solutions","summary":"Stevanato Group announced a partnership with a biotech company to develop customized packaging solutions for their injectable drugs.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPa2w3WkZmWUxmV21URUNBLWVoaUxxVUNzVHNyM01wTF9TUktqUHpKRHlIc2pwLW5PQnpXaHNHWHZsUERLSldlUmN0ZXZvVXNyVWxoMWtrSnFyTWtZUEVvcE5qZTc5TEx0TU5sdzR0V3QtQ1dpUkYzR2JvdTYxYVlSZUV6NFN5Qm9CSDBCZi1FUkNKY0xpcXVZZTVFOFVSbFNQNFAxWm5jZVRrV2lTNmRXLU9Ldk1vOTNkelpKWUZpRW9yYjZfVFN1VnlKOG0wRlRpa0VhUnNINUFrVE0?oc=5","date":"2026-03-12","type":"pipeline","source":"Business Wire","summary":"Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum - Business Wire","headline":"Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPNXR6SWtPb0ZWRFpZTDlRZk9hTjJzWi1jNTEyWFE2SHVPV1o0TWU4Q0UtZ1o3RXpMRTQ4M21jYXhVNlVSNWpOZFlMd1dHU3laR0gwM1Jhckw1bDhsbU5lV2EySGt2alFPVGlua01iRS10ZG9CU2R4MGliU2xpNncyNDMzeVV1NWxCN1NEWHVnTTNvM2ZNaWQ1TXpGT3NKMVNCZXZmQ3V3OWotNDNaTlp5QWRXQy1VYkctN1htVHVfWnBTYVA2Wm5PVVM0TnpzdFVRdmlfU1FiMzl2bUw2SVVR0gHkAUFVX3lxTE5LTzl3REhMRnRqc2ZMRWhjb0NITGw2Wl8wTlljN0hybEIyQWVEYVN5c3RNNFZiM3U2Yy1QOEZjMGt3S3NpTTJvWjFQNmtrZm1wLTJLTGoyWmFIVGN4NENGNDBOa05TdTllaUdDZ0VHcXEwNU9DWlFMSlBPWFpOYVRTa2YtUUdUQmJKN1ZqeE5Ha1ozQXFDV0lyOGtBNmh4SnBOVjczSmU4RFh4SXBhNll6MUc0cVFOZ2FDUEs2QUFheWZXTHpaWXhSNnRUSzBJV3RVV1lkejhoV1pTRUlxZU5HbERldw?oc=5","date":"2026-01-28","type":"pipeline","source":"simplywall.st","summary":"Assessing Stevanato Group (STVN) Valuation After Recent Share Weakness And Undervalued Fair Value Narrative - simplywall.st","headline":"Assessing Stevanato Group (STVN) Valuation After Recent Share Weakness And Undervalued Fair Value Narrative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPc1ZkSGZwWDB0Z3dVNlFkbzlVM3pJcVNoRTVkeF81TFA1akZiZm9DRWk2M3dvWjdUZVl2bWpsdzlEa1FNSWVYNDJUY2VwWXpENjhKX082a19ncWJYU2Y3a2dBYjdEbkxWWWtiTlFhU2xGblZqcDNTNTViVlI1cTlLODRRbHB4dktmVnZNakxoVmxoWUNuNmFPY1ZOR0NLSjVWSUVxcWl5YnpmYkxEdjNEVm5ldUdpXzhEZldKWjRnTE1FeE9yTnBsM2t6Q280c1FMTklJUV84RENDanZJUHJkWkFjZUxkaC1k?oc=5","date":"2025-10-21","type":"pipeline","source":"Business Wire","summary":"Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings - Business Wire","headline":"Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb2tFUWRYZEtjQUVMSVRQWDV3QmtYWjYzRDJINFFuT1NDd196eUF6aUQ5ZzJnakZaVmwzbzIxMFpibjNvYV9iRGsxR01DSE9lc1pzdEhGQ1MtWE1Bc0ZGYXpVck4xbEpWVkZudThCN05uWGg1OU5OVGhSMDZGRWdFN0M4ZTMyVWlzcTVNZ1JQRnU2ZG5ESkQ1eFhrN3RVS1FqZFNMMU13d19hTTRUdjZ4TEJyemtmZElqWlVLTVVTUzg?oc=5","date":"2024-09-26","type":"pipeline","source":"Stevanato Group","summary":"Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU” - Stevanato Group","headline":"Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE11dTQ3ZVFUQllVTHgxeWpuVWRxZVJDQm5WUDdPWW1YZjItSjRyX3Z4SnpBWkpldUZhZlJTV05mVmhLRkU0SThoS1dYTzVjZ2Js?oc=5","date":"2024-04-25","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOeEJvUWF0NERMejVTVmRwYU53R0dzalpfUTNaU21mcU9qM1JKdzhYVU8xV3c3ZFktRDZMNGZWOFhjcUxXcjBmcjdNV014N0ZoX2pzV3dSU2JTUFJpb0JDaGdKRHJVRFBmbm9pZUdYdUVNdkFZSzN5cElkNDktT3JKaFItUDhObFY0Ym0zYmJDM1dyYW9ybFZ2OTZxRDd5WG1PdU13ZlIycnRVc19LdHVEb2ZoY2l6TWdLc3BuMGFEdmx3dw?oc=5","date":"2024-01-24","type":"pipeline","source":"Stevanato Group","summary":"Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and Commercialization - Stevanato Group","headline":"Stevanato Group Launches EZ-fill® Kit and Laboratory Fill and Finish Service to Support Small Batch Drug Development and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQZzVVYWtrM1cwem54T0JPUmQtRDlPdTZuMVFxeDdPclVIOXhvWGpzOEhydExRVWJIdDliclgtYkRmR0Y1V1NyaVE3Z0taRTlGeG1xS0dGbEpUY0JXX1ZHU2h0VnVORHlZT2w3TXVLVm1UTmV3TTB6bjZMLXN0VVlDTlZVek9XUDY0eU5TUnNxdGNKbDA?oc=5","date":"2023-03-21","type":"pipeline","source":"Drug Delivery Business","summary":"Stevanato Group, Thermo Fisher to bring on-body drug delivery system to market - Drug Delivery Business","headline":"Stevanato Group, Thermo Fisher to bring on-body drug delivery system to market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOZDE4dkxQODRPVldvdF9qWlRETnhpYUppU0x4RmlhOVpQY1BaNlgyeHBfUEtJQ0VrcmZvRTVTdkVhMDE3T1R1VDFtLU5mWkhiMlloN01XVHNSc0pTYnJXWXhYa3FCN29GNWRzZTRkSk9wOE4xbzFRVlFTUnNTTmhkU1l3ejhGNzJSbnlXcmlwRVYtSG5NRDVFNVJOYVQwX3hqMDg0TW02anlJdDRxTkxqZk5RZUF0QmJWd1RTdEdmeUo1QzRp?oc=5","date":"2023-03-21","type":"pipeline","source":"Stevanato Group","summary":"Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market - Stevanato Group","headline":"Stevanato Group Collaborates with Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQME14RlZKOHVvQ24wN1QxdUpYaU5FLThPcldWdUlEMENITHptM2hNWGF3WjJNclRaUFRseWZIYkRoaEpMZ0YyVjJqLV80U1NZaURsOVI0UHltNkREYnZpVk9ZaDB4U2pSamNXdV9TSWVKRTR5cHhFcXVoZVJGXy03bGg3c0RSWGFoOE9DcURtTDItaGJQQWJ6TVJULWJKVXpsQmNkQjM1M1BHcFk3VXhxd2VaeWFrNWJjZ3FyWkEtRnZUdw?oc=5","date":"2023-01-24","type":"pipeline","source":"Stevanato Group","summary":"Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma - Stevanato Group","headline":"Stevanato Group Collaborates with Transcoject to Provide Pre-Fillable Syringe Polymer Options for Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQbXRTWXhFRkRkbzlYZXpHTnVCZjZTdHVOd2hwRWV2TUFjbzJqY29JLTB4eGJJX3RpdEllbUpkelE4VjVobXZEcEtTWmR3bC0waXdIQXJLdzdfN1p3ZDJOTjVCV1JOT1lwbjFuRGZhQ0hYYUFEcHBySUlMWGp3endaV1h4LVEtM1o3MUpraFFZM3daczR5LWcyRmFOZkNIbE91ZERMQ280U2tvQ2tfMlhhY1pNTHhVcmVjczRibUhmaXp1aFZJa2dqVTRFb1k?oc=5","date":"2021-07-15","type":"pipeline","source":"renaissancecapital.com","summary":"STVN IPO News - Italian drug vial supplier Stevanato Group prices downsized US IPO at $21 low end - renaissancecapital.com","headline":"STVN IPO News - Italian drug vial supplier Stevanato Group prices downsized US IPO at $21 low end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQS0xvSFdnNWh2TWd0OXhjdjZFN1YwRC11X21YcTIyR2RHZTRjOG5YQUtERzBoempzOEs3UWxhMXZYVXpNSDNZM1Q1d0ZmZUVPYjJrb1Z3ckV2OWtsX3lHc0gyeW1HcGhBTE5FMkZwMGlucjFnRDVfSTQwOEtQcXBRMzlfN3lOR3hOS2dJd3ljdnVyTnFFZElFdmZhRWFlNk1md19tM3ZaejRSZmttWHlPTzBldl9kMzNDb1RKcGlOWWRENG5CNXNjZmtzS0w?oc=5","date":"2021-07-07","type":"pipeline","source":"renaissancecapital.com","summary":"STVN IPO News - Italian drug container supplier Stevanato Group sets terms for $900 million US IPO - renaissancecapital.com","headline":"STVN IPO News - Italian drug container supplier Stevanato Group sets terms for $900 million US IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNOTV1SG0teEVsRG1WeWhKRjZVdTMtcXRCZFFta0xiaFhteXRpOFhBZXoxaGVuakxBaWtHaEZxQWJudFNKTnE1OXB2anRsSmVwckpETTlsbHBMYVpjREVNWFVpb29pc2xjRjBVSXlEajVUZVlOYUx6Wkh1YzFCZFBNR01nQWY2UEFRZnpIYVotSUpmaUI2Z0RBNGNEam1lS1ZIWjhrRUt2eTRfNDNvVkJqQQ?oc=5","date":"2021-06-21","type":"pipeline","source":"renaissancecapital.com","summary":"STVN IPO News - Italy's Stevanato Group files for a $100 million US IPO - renaissancecapital.com","headline":"STVN IPO News - Italy's Stevanato Group files for a $100 million US IPO","sentiment":"neutral"}],"patents":[{"drugName":"Eprex","drugSlug":"epoetin-alfa","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Lupron","drugSlug":"leuprolide","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["West Pharmaceutical Services","Becton Dickinson","Gerresheimer"],"therapeuticFocus":["Oncology","Hematology"],"financials":{"source":"yahoo_finance","revenue":1385843459.0526001,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1385843459.0526001},{"period":"2024-12-31","value":1289761683.2748},{"period":"2023-12-31","value":1267936916.9022002},{"period":"2022-12-31","value":1149158879.424}],"grossProfit":401724299.38680005,"grossProfitHistory":[{"period":"2025-12-31","value":401724299.38680005},{"period":"2024-12-31","value":353176402.1517},{"period":"2023-12-31","value":397071261.99990004},{"period":"2022-12-31","value":373599299.3643}],"rdSpend":29714953.294800002,"rdSpendHistory":[{"period":"2025-12-31","value":29714953.294800002},{"period":"2024-12-31","value":36995327.132400006},{"period":"2023-12-31","value":41672897.229600005},{"period":"2022-12-31","value":40171729.0041}],"sgaSpend":139089953.38230002,"operatingIncome":232244159.06430003,"operatingIncomeHistory":[{"period":"2025-12-31","value":232244159.06430003},{"period":"2024-12-31","value":188250000.15060002},{"period":"2023-12-31","value":234485981.49600002},{"period":"2022-12-31","value":224802570.27330002}],"netIncome":163363317.88770002,"netIncomeHistory":[{"period":"2025-12-31","value":163363317.88770002},{"period":"2024-12-31","value":137591121.60540003},{"period":"2023-12-31","value":170129673.0333},{"period":"2022-12-31","value":166879673.03070003}],"eps":0.51,"epsHistory":[{"period":"2025-12-31","value":0.51},{"period":"2024-12-31","value":0.43},{"period":"2023-12-31","value":0.55},{"period":"2022-12-31","value":0.54}],"cash":152573598.2529,"cashHistory":[{"period":"2025-12-31","value":152573598.2529},{"period":"2024-12-31","value":114801401.96100001},{"period":"2023-12-31","value":81310747.72860001},{"period":"2022-12-31","value":267219626.38200003}],"totalAssets":2971932245.3682003,"totalLiabilities":1235342290.7079,"totalDebt":547786215.3915,"equity":1736545562.1369002,"operatingCashflow":334202103.07110006,"operatingCashflowHistory":[{"period":"2025-12-31","value":334202103.07110006},{"period":"2024-12-31","value":181981308.5568},{"period":"2023-12-31","value":122908878.60300002},{"period":"2022-12-31","value":120691588.8816}],"capex":-321299065.6776,"capexHistory":[{"period":"2025-12-31","value":-321299065.6776},{"period":"2024-12-31","value":-366321261.9753},{"period":"2023-12-31","value":-516272196.6747},{"period":"2022-12-31","value":-284026869.38610005}],"freeCashflow":12903037.3935,"dividendsPaid":-17216121.5091,"buybacks":null,"employees":6010,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":34997663.5794,"ebit":47207943.96300001,"ebitda":76005841.1823,"period":"2026-03-31","revenue":319595794.64820004,"epsBasic":0.1,"netIncome":32744158.904700004,"rdExpense":6824766.3606,"epsDiluted":0.1,"grossProfit":87824766.4254,"operatingIncome":45253504.7091},{"sga":29970794.416500002,"ebit":78688084.17510001,"ebitda":107419392.6093,"period":"2025-12-31","revenue":404768691.91260004,"epsBasic":0.17,"netIncome":55554906.586500004,"rdExpense":6789719.631600001,"epsDiluted":0.17,"grossProfit":124882009.4457,"operatingIncome":81873831.84120001},{"sga":36037383.2064,"ebit":59461448.64570001,"ebitda":59461448.64570001,"period":"2025-09-30","revenue":354167056.35810006,"epsBasic":0.13,"netIncome":42130841.155200005,"rdExpense":8934579.446400002,"epsDiluted":0.13,"grossProfit":103387850.55000001,"operatingIncome":61589953.320300005},{"sga":37500000.03,"ebit":59112149.580000006,"ebitda":59112149.580000006,"period":"2025-06-30","revenue":327102804,"epsBasic":0.11,"netIncome":34696261.71,"rdExpense":7009345.800000001,"epsDiluted":0.11,"grossProfit":91822429.98,"operatingIncome":48364486.02},{"sga":32483644.885800004,"ebit":42685747.6977,"ebitda":66779205.660900004,"period":"2025-03-31","revenue":299761682.4828,"epsBasic":0.1,"netIncome":30977803.763100002,"rdExpense":6928738.3233,"epsDiluted":0.1,"grossProfit":81648364.5513,"operatingIncome":40453271.0604}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":18,"previousClose":17.86,"fiftyTwoWeekHigh":28,"fiftyTwoWeekLow":12.89,"fiftyTwoWeekRange":"12.89 - 28.0","fiftyDayAverage":15.51,"twoHundredDayAverage":20.37,"beta":0.76,"enterpriseValue":6091343556.274944,"forwardPE":21.1,"priceToBook":2.72,"priceToSales":4.08,"enterpriseToRevenue":4.33,"enterpriseToEbitda":18.07,"pegRatio":0,"ebitda":337125009.61549443,"ebitdaMargin":24,"freeCashflow":-66657855.19351321,"operatingCashflow":305757009.59040004,"totalDebt":526383177.99120003,"debtToEquity":29.4,"currentRatio":1.63,"returnOnAssets":5.3,"returnOnEquity":9.6,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":24.83,"targetHighPrice":32,"targetLowPrice":17.5,"dividendRate":0.06,"payoutRatio":0.11,"fiveYearAvgDividendYield":0,"exDividendDate":1749081600,"insiderHeldPercent":1.6,"institutionHeldPercent":98.6,"sharesOutstanding":49709718,"floatShares":48946832,"sharesShort":886332,"shortRatio":1.49,"shortPercentOfFloat":0.3,"epsTrailing":0.6,"epsForward":0.85,"revenuePerShare":4.41,"bookValue":6.61,"officers":[{"age":52,"name":"Mr. Franco  Stevanato","title":"CEO & Executive Chairman"},{"age":52,"name":"Mr. Marco  Dal Lago","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Lisa  Miles","title":"Chief Communications & Investor Relations Officer"},{"age":null,"name":"Ms. Carla  Costa","title":"Chief Human Resources Officer"},{"age":58,"name":"Mr. Mauro  Stocchi","title":"Chief Business Officer"},{"age":null,"name":"Mr. Michele  Monico","title":"President of DDS & IVD Business Unit"},{"age":null,"name":"Mr. Raffaele  Pace","title":"President of Engineering Business Unit"}],"industry":"Medical Instruments & Supplies","irWebsite":"","website":"https://www.stevanatogroup.com","phone":"39 04 99 31 811"}}